A Phase I/II Study of GB1275, a First-in-class Oral CD11b Modulator, Alone, and Combined with Pembrolizumab in Specified Advanced Solid Tumors or with Chemotherapy in Metastatic Pancreatic Cancer (KEYNOTE-A36).
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined